Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KSR as a therapeutic target for Ras-dependent cancers

24 Mar 2017

Abstract excerpt

INTRODUCTION: Targeting downstream effectors required for oncogenic Ras signaling is a potential alternative or complement to the development of more direct approaches targeting Ras in the treatment of Ras-dependent cancers. Areas covered: Here we review literature pertaining to the molecular scaffold Kinase Suppressor of Ras (KSR) and its role in promoting signals critical to tumor maintenance. We summarize the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Melanoma and MAPK Pathways
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28333549
DOI: 10.1080/14728222.2017.1311325

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KSR as a therapeutic target for Ras-dependent cancersPMID 28333549Read ↗

Coordinating ERK signaling via the molecular scaffold Kinase Suppressor of RasSemantic proximity Read ↗

Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.Semantic proximity Read ↗

Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo.Semantic proximity Read ↗

Biology, pathology, and therapeutic targeting of RAS.Semantic proximity Read ↗

Kinase Suppressor of RAS 1 (KSR1) maintains the transformed phenotype of BRAFV600E mutant human melanoma cellsSemantic proximity Read ↗

The Ins and Outs of RAS Effector Complexes.Semantic proximity Read ↗

Past, Present, and Future of Targeting Ras for Cancer Therapies.Semantic proximity Read ↗

Targeting pathological ERK1/2 signaling in cancer and beyondSemantic proximity Read ↗

Targeting the RAS oncogene.Semantic proximity Read ↗

Oncogenic RAS: From Its Activation to Its Direct Targeting.Semantic proximity Read ↗

Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.Semantic proximity Read ↗

Targeting oncogenic Ras signaling in hematologic malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.